The authors have performed a potentially valuable new kind of analysis in connectomics, mapping to an interesting developmental problem of synaptic input to sensory neurons. While the analysis itself ...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The publication of the ...
GRAND JUNCTION, Colo. (KRDO) - The man who disrupted a flight from Virginia to California - forcing it to make an emergency landing in Grand Junction - is now facing federal charges. The U.S. Attorney ...
Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
While BCG remains standard of care adjuvant treatment for high-risk nonmuscle invasive bladder cancer (NMIBC), predicting response to BCG therapy is difficult. PD-L1 expression in the tumor ...
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. In this paper, the ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1. In a 2 to 10 vote, the FDA’s ...
The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. This time, the agency is considering limiting these immunotherapies’ use in stomach cancer and esophageal ...
ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months. Surgical outcomes in patients with non-small cell lung cancer receiving neoadjuvant ...
Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback